RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell-mediated cytotoxicity.
CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell-mediated cytotoxicity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌细胞对自然杀伤(NK)细胞介导的细胞毒作用的敏感性取决于其表面表达活化性和抑制性配体的平衡。尽管多种类型的癌细胞可被NK细胞杀伤,但非小细胞肺癌(NSCLC)细胞对NK细胞介导的细胞毒作用相对耐药。
在本研究中,我们发现几种NSCLC细胞系对NK细胞介导的细胞毒作用具有不同的敏感性:NCI-H522细胞高度敏感,而A549、NCI-H23、NCI-H1915和NCI-H1299则耐药。在CD48、HLA-A/B/G、ICAM-1、MICA/B和ULBPs等活化性配体中,只有CD48使NCI-H522细胞对NK细胞介导的细胞毒作用敏感,这一点通过使用CD48 siRNA和中和抗体得到了证实。CD48阳性的NCI-H522细胞与NK细胞建立的接触比CD48阴性的A549细胞和转染CD48 siRNA的NCI-H522细胞更为稳定。
综上所述,这些数据表明CD48阳性的NSCLC细胞可能对NK细胞介导的细胞毒作用敏感,这为如何筛选可能对NK细胞治疗有反应的NSCLC患者提供了信息。
The susceptibility of cancer cells to natural killer (NK) cell-mediated cytotoxicity depends on the balance of activating and inhibitory ligands expressed on their surface. Although many types of cancer cells are killed by NK cells, non-small-cell lung cancer (NSCLC) cells are relatively resistant to NK cell-mediated cytotoxicity. In this study, we showed that several NSCLC cell lines have differential sensitivity to NK cell-mediated cytotoxicity: NCI-H522 cells were highly sensitive, but A549, NCI-H23, NCI-H1915, and NCI-H1299 were resistant.
Among activating ligands such as CD48, HLA-A/B/G, ICAM-1, MICA/B, and ULBPs, only CD48 rendered NCI-H522 cells susceptible to NK cell-mediated cytotoxicity, which was proved by using CD48 siRNA and neutralizing antibody. CD48-positive NCI-H522 cells established a more stable contact with NK cells than did CD48-negative A549 and CD48 siRNA cell-transfected NCI-H522 cells.
Taken together, these data demonstrate that CD48-positive NSCLC cells might be susceptible to NK cell-mediated cytotoxicity, which provide information on how to stratify NSCLC patients potentially responsive to NK-cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。